Allergan Inc.: PharmaVitae Report | ReportsnReports

Allergan Inc.: PharmaVitae Report 

Allergan’s prescription sales will experience positive year-on-year growth rates until sales turn to decline following key patent expiries in 2014. Although generic erosion of Allergan’s ophthalmic franchise will drive a decline in revenues, gains generated by uptake of Botox will offset these negative trends leading to positive growth overall.

Features and benefits

• Gain insight into Allergan’s strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/143558-allergan-inc-pharmavitae-report.html

Major points covered in Table of Contents of this report include

• Executive Summary
• STRATEGIC INSIGHT
• COMPANY INTRODUCTION
• SALES ANALYSIS
• FINANCIAL ANALYSIS
• PRODUCT ANALYSIS
• APPENDIX
• List of Tables
• List of Figures

Explore Comprehensive list of more than 284 Tables & Figures available in the report Allergan Inc.: PharmaVitae Report

Report Details:

Published: December 2011
No. of Pages: 85

Price: Single User License – US$5700       Corporate User License – US$14250

US Generics Overview | ReportsnReports

US Generics Overview

This report gives an overview of the US generics market.

Your key questions answered

• See how the US generics market is at a turning point as the number of brands available for genericization begins to slow
• Assess how companies are maintaining growth by targeting niches within the US generics market.

Features and benefits

• Analysis of top-line trends in the US generics market
• Identification of opportunities for growth as the number of expiries available for genericization begins to slow

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/143556-us-generics-overview.html

Major points covered in Table of Contents of this report include

• EXECUTIVE SUMMARY
• US GENERICS MARKET OVERVIEW
• SPECIALIZED MARKET SEGMENTS
• LEGISLATIVE DEVELOPMENTS
• APPENDIX

Explore Comprehensive list of more than 284 Tables & Figures available in the report US Generics Overview

Report Details:

Published: December 2011
No. of Pages: 48

Price: Single User License – US$5700       Corporate User License – US$14250

Epidemiology: Hypertension in China – Increasingly Western lifestyles drive up prevalence

Epidemiology: Hypertension in China – Increasingly Western lifestyles drive up prevalence

The number of total prevalent cases of hypertension in China will increase in the next decade from approximately 263 million in 2010 to 419 million in 2020.

In 2010, Datamonitor estimates that there were approximately 263 million people with hypertension China; 53% of these were in men

In China, the majority of hypertension cases are in individuals aged 60 years and above. Lifestyle risk factors and aging populations are driving the hypertension epidemiology in China

Features and benefits

Gain insight to market potential, including a robust 10-year epidemiology forecast of prevalent hypertension in China

Understand the key epidemiologic risk factors associated with hypertension in China.

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/143561-epidemiology-hypertension-in-china-increasingly-western-lifestyles-drive-up-prevalence.html

Major points covered in Table of Contents of this report include

• OVERVIEW
• EXECUTIVE SUMMARY
• DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
• GLOBAL VARIATION AND HISTORICAL TRENDS
• DRIVERS OF HYPERTENSION EPIDEMIOLOGY
• EPIDEMIOLOGIC FORECASTING OF HYPERTENSION
• EPIDEMIOLOGIC RESULTS
• DISCUSSION
• BIBLIOGRAPHY
• APPENDIX

Explore Comprehensive list of more than 284 Tables & Figures available in the report Epidemiology: Hypertension in China – Increasingly Western lifestyles drive up prevalence

Report Details:

Published: December 2011
No. of Pages: 48

Price: Single User License – US$ 7600      Corporate User License – US$ 19000

Epidemiology: Type 2 Diabetes – Rising obesity and aging populations are driving diabetes trends

Epidemiology: Type 2 Diabetes – Rising obesity and aging populations are driving diabetes trends 

The number of diagnosed prevalent cases of type 2 diabetes will increase across all seven major markets from approximately 39.4 million in 2010 to 52.5 million in 2020.

In 2010, Datamonitor estimates that there were approximately 16 million people in the US diagnosed with diabetes. In Japan, there were approximately 7.8 million prevalent diabetes cases.

In the five major EU markets (France, Germany, Italy, Spain, and the UK), there were about 15.6 million people diagnosed with type 2 diabetes in 2010.

Request a Sample for or Inquire before buying the report @  

http://www.reportsnreports.com/reports/143567-epidemiology-type-2-diabetes-rising-obesity-and-aging-populations-are-driving-diabetes-trends.html

Features and benefits

• Gain insight into market potential, including a robust 10-year epidemiology forecast of prevalent type 2 diabetes mellitus.
• Understand the key epidemiologic risk factors associated with type 2 diabetes.

Major points covered in Table of Contents of this report include

• OVERVIEW
• EXECUTIVE SUMMARY
• DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
• GLOBAL VARIATION AND HISTORICAL TRENDS
• DRIVERS OF HYPERTENSION EPIDEMIOLOGY
• EPIDEMIOLOGIC FORECASTING OF HYPERTENSION
• EPIDEMIOLOGIC RESULTS
• DISCUSSION
• BIBLIOGRAPHY
• APPENDIX

Explore Comprehensive list of more than 67 Tables & Figures available in the report Epidemiology: Type 2 Diabetes – Rising obesity and aging populations are driving diabetes trends

Report Details:

Published: December 2011
No. of Pages: 48

Price: Single User License – US$ 7600      Corporate User License – US$ 19000